Preparatory Work to Assess Adherence to Oral Chemotherapy Among Patients With Chronic Myeloid Leukemia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Myeloid Leukemia
- Sponsor
- Wake Forest University Health Sciences
- Enrollment
- 86
- Locations
- 1
- Primary Endpoint
- Patient Demographic and Health Behaviors Questionnaire
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
This study to find out more about how patients take their anticancer medications and challenges related to taking cancer medications.
Detailed Description
120 patients with Chronic Myeloid Leukemia (CML) who are currently prescribed an oral anti-cancer agent from up to 6 CCDR NCORP sites to complete a brief interviewer administered survey to assess medication adherence and related factors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient is diagnosed with Chronic Myeloid Leukemia (CML) and is receiving care for CML at a participating CCDR NCORP practice,
- •Patient had been prescribed one of the following oral anticancer agents for CML for ≥30 days (Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib). Prior use of any of these medications is allowed, as long as they have been on a stable regimen for at least 30 days prior to enrollment.
- •Patient is 18 years of age or older
Exclusion Criteria
- •Patient does not speak English or requires an interpreter for medical visits
- •Patient is cognitively impaired, as determined by the referring provider
Outcomes
Primary Outcomes
Patient Demographic and Health Behaviors Questionnaire
Time Frame: Study 1 day Visit
Questions will be asked about the participants demographic background and health behaviors.
Brief Medication Questionnaire (BMQ)
Time Frame: Study 1 day Visit
A self-report tool for screening adherence and barriers to adherence. The tool includes a 5-item Regimen Screen that asks patients how they took each medication in the past week, a 2-item Belief Screen that asks about drug effects and bothersome features, and a 2-item Recall Screen about potential difficulties remembering.
Single Item Adherence Measure 1
Time Frame: Study 1 day Visit
This is a single question. This measure was developed to serve as simple means of identifying sub-optimal adherence which could help identify at-risk patients for interventions.
Single Item Adherence Measure 2
Time Frame: Study 1 day Visit
This single item was developed to evaluate self-report adherence to medication and has demonstrated low patient burden and the ability to predict adherence-related clinical outcomes as good or better than other adherence measures.
Secondary Outcomes
- REALM-SF(Study 1 day Visit)
- Medications Adherence Reasons Scale (MARS)(Study 1 day Visit)